The global consumer goods industry is witnessing a landmark merger and acquisition – American consumer goods giant Kimberly-Clark announced that it will acquire all shares of Kenvue for $48.7 billion (approximately RMB 346.7 billion). This record-breaking deal is expected to be completed in the second half of 2026 and will create a consumer health giant with annual revenue of over $32 billion, reshaping the global market competition landscape.
This acquisition represents a strategic breakthrough for both companies. For Kimberly-Clark, it's a crucial step in overcoming growth bottlenecks. As a century-old company with renowned brands like Kleenex, Kotex, and Huggies, it has recently been struggling with sluggish growth in traditional product categories, with rising raw material prices continuously eroding profits. Meanwhile, Corfu, a consumer health giant spun off from Johnson & Johnson, covers three major sectors: personal care, skin health, and basic health. It owns 10 super brands with annual sales exceeding $1 billion, including Tylenol, Listerine, Neutrogena, Dabao, and Band-Aid. This acquisition perfectly fills the gap in Kimberly-Clark's high-margin health sector, helping it transform from a "consumer goods company" into a "healthcare leader."
For KEF, this transaction represents a realistic option to escape the predicament of independent operation. Since its independent listing in 2023, KEF's performance has been under continuous pressure, with net profit plummeting by 38% in 2024 and revenue declining by nearly 4% year-on-year in the first half of 2025, while the competitiveness of several of its brands has weakened. Joining Kimberly-Clark will provide it with stable financial support, a mature supply chain system, and global channel resources, which is expected to solve its growth problems.
The core value of the transaction lies in its powerful synergies. At the brand level, Kimberly-Clark's daily care products complement Ceftriax's health and wellness product line, achieving full-scenario coverage from maternal and infant care and household paper products to pharmaceuticals and skincare, building a brand matrix covering the entire human life cycle. In terms of efficiency, the two companies expect to achieve $1.9 billion in cost synergies and $500 million in revenue synergies, optimizing cost structures through supply chain integration and channel sharing. At the channel level, Kimberly-Clark's maternal and infant channels and Ceftriax's pharmacy channels can mutually penetrate each other, improving terminal sales per square meter.
This merger will also reshape the competitive landscape of the industry. The merged company's revenue is second only to Procter & Gamble, directly competing with P&G in the health and wellness sector, potentially triggering a new wave of mergers and acquisitions in the industry. In the Chinese market, Ceftriax has already established 2 R&D centers, 4 factories, and 10 logistics centers. Kimberly-Clark can leverage this foundation to deepen its localization strategy, further activating the potential of local brands such as Dabao, and seizing the opportunities in China's daily health and wellness consumer market.
However, the transaction still faces multiple challenges. Having just completed its spin-off from Johnson & Johnson, Kofu's corporate culture is not yet fully formed, making integration with Kimberly-Clark quite challenging. The debt burden from the massive acquisition and antitrust scrutiny from regulatory agencies all pose challenges to the subsequent integration process.
This 346.7 billion yuan strategic acquisition is essentially an inevitable choice for traditional giants in response to industry changes. Kimberly-Clark is rapidly building competitive barriers through capital means, while Kofu is leveraging its platform resources to restart its growth engine. The collaboration between the two is not merely a simple addition of scale, but a deep integration of category synergy and strategic upgrades. Whether this integration can achieve the expected synergistic effects and drive the global daily health consumer goods industry towards a more concentrated and professional direction remains to be seen and deserves continued market attention.